Vestmark Advisory Solutions’s Intellia Therapeutics NTLA Stock Holding History

Vestmark Advisory Solutions’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.02M	Sell	532,817 -17,327	-3%	-$243K	0.08%	250
2026 Q1	$7.05M	Buy	550,144 +106,217	+24%	+$1.35M	0.08%	262
2025 Q4	$3.99M	Buy	443,927 +146,361	+49%	+$2.01M	0.05%	357
2025 Q3	$5.14M	Sell	297,566 -340,776	-53%	-$4.2M	0.1%	206
2025 Q2	$5.99M	Buy	638,342 +326,460	+105%	+$2.68M	0.09%	173
2025 Q1	$2.22M	Sell	311,882 -63,409	-17%	-$640K	0.06%	312
2024 Q4	$5.41M	Buy	375,291 +47,045	+14%	+$734K	0.19%	111
2024 Q3	$6.75M	Sell	328,246 -27,079	-8%	-$624K	0.25%	81
2024 Q2	$7.95M	Sell	355,325 -65,072	-15%	-$1.55M	0.33%	63
2024 Q1	$11.6M	Buy	420,397 +154,416	+58%	+$4.29M	0.5%	42
2023 Q4	$8.11M	Buy	+265,981	New	+$7.64M	0.41%	53

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Vestmark Advisory Solutions's NTLA Position: Q2 2026 in Review

Vestmark Advisory Solutions reduced its Intellia Therapeutics (NTLA) stake by 3.1% in Q2 2026, selling an estimated $243K and leaving 532,817 shares worth $9.02M. The position accounts for 0.08% of the portfolio, ranked #250.

Vestmark Advisory Solutions first reported a position in NTLA in Q4 2023 and has held it in 11 quarters since. The position peaked at $11.6M in Q1 2024. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Vestmark Advisory Solutions held 532,817 shares of Intellia Therapeutics worth $9.02M as of Q2 2026.
Vestmark Advisory Solutions sold 17,327 Intellia Therapeutics shares in Q2 2026, an estimated $243K.
Intellia Therapeutics made up 0.08% of Vestmark Advisory Solutions's portfolio in Q2 2026, its #250 holding.
Vestmark Advisory Solutions first reported a position in Intellia Therapeutics in Q4 2023 and has held it in 11 quarters since.
Vestmark Advisory Solutions's Intellia Therapeutics position peaked at $11.6M in Q1 2024.
329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Vestmark Advisory Solutions's 13F filing for Q2 2026, filed 14 Aug 2026.